Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
6.80
-0.02 (-0.29%)
At close: Sep 17, 2025, 4:00 PM EDT
6.76
-0.04 (-0.59%)
After-hours: Sep 17, 2025, 4:14 PM EDT
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $8.70M in the quarter ending June 30, 2025, a decrease of -55.82%. This brings the company's revenue in the last twelve months to $93.95M, down -14.98% year-over-year. In the year 2024, Wave Life Sciences had annual revenue of $108.30M, down -4.42%.
Revenue (ttm)
$93.95M
Revenue Growth
-14.98%
P/S Ratio
11.27
Revenue / Employee
$326,201
Employees
288
Market Cap
1.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
WVE News
- 14 days ago - Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript - Seeking Alpha
- 14 days ago - Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday? - Benzinga
- 14 days ago - Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 6 weeks ago - Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 - GlobeNewsWire
- 2 months ago - Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months - Seeking Alpha
- 3 months ago - Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions - GlobeNewsWire